Immunosuppressive treatment for refractory ulcerative colitis - Where do we stand and where are we going?

European Journal of Gastroenterology and Hepatology

Volumn 9, Issue 9, 1997, Pages 842-849

  Schölmerich, Jürgen ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

6 mercaptopurine; Azathioprine; Cyclosporin A; Experimental treatments; Immunosuppression; Methotrexate; Refractory UC

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 10; MERCAPTOPURINE; METHOTREXATE; STEROID;

DRUG EFFICACY; ELECTIVE SURGERY; EUROPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS;

EID: 0030773276     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199709000-00004     Document Type: Review

References (96)

1. Kornbluth AA, Salomon P, Sacks HS, et al.: Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993, 16:215-218. Meaningful meta-analysis of standard treatment of UC.
2. Langholz E, Munkholm P, Davidsen M, et al.: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994, 107:3-11. Interesting study, proving the value of long-term maintenance treatment and surgery.
3. Marshall JK, Irvine EJ: Rectal aminosalicylate therapy for distal ulcerative colitis: a metaanalysis. Aliment Pharmacol Ther 1995, 9:293-300. Meta-analysis of rectal treatment showing efficacy of 5-aminosalicylic acid (5-ASA).
4. Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118:540-549. Meta-analysis demonstrating efficacy of sulphasalazine and 5-ASA.
5. Kjeldsen J: Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand J Gastroenterol 1993, 28:821-826. Interesting study indicating a relatively large number of patients being refractory to steroids.
6. Ferzoco S, Becker JM: Does aggressive medical therapy for acute ulcerative colitis result in a higher incidence of staged colectomy? Arch Surg 1994, 129:420-424. Interesting study showing that aggressive medical therapy increases the incidence of urgent staged colectomy and morbidity, hospital stay and cost.
7. Jewell D, Caprilli R, Mortensen N, et al.: Indications and timing of surgery for severe ulcerative colitis. Int Gastroenterol 1991, 4:161-164. Comprehensive review of differential treatment in severe UC.
8. Pemberton JH, Kella KA, Beart RW, et al.: Ileal pouch-anal anastomosis for chronic ulcerative colitis. Ann Surg 1987, 206:504-513. Excellent and comprehensive assessment of ileal pouch-anal anastomosis.
9. Sandborn WJ: Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994, 107:1856-1860. Excellent review of all problems associated with pouchitis.
10. Choi PM, Targan SR: Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci 1994, 39:1885-1892. Comprehensive review of new approaches for immune modulating therapy.
11. Griffin MG, Miner PB: Refractory distal colitis - explanations and options. Aliment Pharmacol Ther 1996, 10:39-48. Review describing therapeutic options in refractory distal colitis.
12. Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91:423-433. Excellent review of immunosuppressants in IBD.
13. Shah SA, Peppercorn MA: A comparative review of topical therapies for inflammatory bowel disease. Clin Immunother 1996, 2:117-129. Extensive description of topical therapy in IBD.
14. Shanahan F, O'Sullivan GC, Collins JK: Immunosuppressive agents in inflammatory bowel disease: current status and future prospects. Can J Gastroenterol 1994, 8:383-387. Review of immunosuppressive agents in IBD.
15. Lennard L: The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43:329-339. Helpful review of the pharmacology of the purine analogues.
16. Kirk AP, Lennard-Jones JE: Controlled trial of azathioprine in chronic ulcerative colitis. BMJ 1982, 284:1291-1292. Small controlled trial indicating activity of azathioprine.
17. Rosenberg JL, Wall AJ, Levin B, et al.: A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975, 69:96-99. Small trial showing significant advantage of azathioprine.
18. Adler DJ, Korelitz BI: The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990, 85:717-722. Report on a series of patients treated with 6-mercaptopurine.
19. Ardizzone S, Molteni P, Imbesi V, et al.: Efficacy of azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. Gut 1995, 36(suppl. 2A):244. Series of 56 patients published only as an abstract indicating effectiveness and safety in precolectomy patients.
20. Hawthorne AB, Logan RFA, Hawkey CJ: Azathioprine (AZA) in resistant ulcerative colitis (UC). Gastroenterology 1989, 96:A201. Report on 52 patients indicating tolerance for 41 and efficacy in 35, published only as abstract.
21. Lobo AJ, Forster PN, Burke DA, et al.: The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990, 33:374-377. Series of 47 patients indicating efficacy in 50-60% of patients.
22. Steinhart AH, Baker JP, Brzezinski A, et al.: Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 1990, 12:271-275. Series of 16 patients indicating response in 75%.
23. Hawthorne AB, Logan RFA, Hawkey CJ, et al.: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992, 305:20-22. Randomized trial indicating benefit of 2-year maintenance treatment with azathioprine.
24. Bouhnik Y, Lémann M, Mary JY, et al.: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347:215-219. Controlled trial in Crohn's disease indicating that treatment should be continued for several years.
25. George J, Pou R, Bodian C, et al.: Present: 6-mercaptopurine (6 MP) is effective in chronic ulcerative colitis (CUC) but how long do you use it? Gastroenterology 1994, 106:A686. Report on 105 patients indicating the need for long-term treatment, published only as an abstract.
26. Present DH, Meltzer SJ, Krumholz MP, et al.: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989, 111:641-649. Important report on toxicity based on experience with 396 patients.
27. Burke DA, Dixon MF, Axon ATR: Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia. J Clin Gastroenterol 1989, 11:327-330. Case report giving the first hint that cytopenia may be associated with clinical response.
28. D'Haens G, Callens J, Hiele M, et al.: Reduction in neutrophil and not lymphocyte count is associated with favourable response to azathioprine therapy in refractory Crohn's disease. Gastroenterology 1995, 108:A809. Larger series of patients with Crohn's disease indicating the need to reach neutropenia for therapeutic effect, published only as an abstract.
29. Sandborn WI, van Os EC, Zins BI, et al.: An intravenous loading dose of azathioprine decreases the time to response in patients with inflammatory and fistulous Crohn's disease. Gastroenterology 1995, 108:A910. Interesting study using, for the first time, high dose intravenous loading of azathioprine in Crohn's disease, published only as an abstract.
30. Berg PS, George J, Present DH, et al.: 6MP - is leukopenia required to induce remission in the treatment of ulcerative colitis? Gastroenterology 1996, 110:A863. Report on 101 patients with UC again showing an association of neutropenia and therapeutic response, published only as an abstract.
31. Connell WR, Kamm M, Dickson M, et al.: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249-1252. Retrospective analysis of a large patient cohort indicating no risk of neoplasia after azathioprine treatment in IBD.
32. Verhave M, Winter HS, Grand RJ: Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990, 117:809-814. Report on 21 children (9 with UC) treated with azathioprine showing clinical usefulness.
33. Alstead EM, Ritchie JK, Lennard-Jones JE, et al.: Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990, 99:443-446. Analysis of 16 pregnancies indicating safety during pregnancy.
34. Connell WR: Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women. Inflamm Bowel Dis 1996, 2:33-47. Important review of drug safety in pregnant and nursing women with IBD.
35. Francella A, Dayan A, Rubin P, et al.: 6-Mercaptopurine (6-MP) is safe therapy for child bearing patients with inflammatory bowel disease (IBD). A case controlled study. Gastroenterology 1996, 110:A909. Series of 167 pregnancies involving 6-MP treatment showing no association with congenital abnormalities and abortion, published only as an abstract.
36. Schölmerich J: Therapie chronisch entzündlicher Darmerkrankungen - Colitis ulcerosa und Morbus Crohn. In Klinik der Gegenwart. Edited by Peter HH, Pfreundschuh M, Philipp T, et al. München: Urban und Schwarzenberg; 1996 IV, 16: 1-44. Review of the treatment of IBD, state of the art 1996.
37. Van Os EC, Zins BJ, Sandborn WJ, et al.: Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996, 39:63-68. Interesting study on bioavailability of 6-mercaptopurine with targeted administration to the gut.
38. Egan LJ, Sandborn WJ: Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996, 71:69-80. Excellent review on pharmacology and clinical efficacy of methotrexate in IBD.
39. Feagan B, Rocon J, Fedorak R, e tal.: Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995, 332:292-297. Important multicentre trial indicating methotrexate efficacy in Crohn's disease.
40. Baron TH, Truss CD, Elson CO: Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993, 38:1851-1856. Open study on 18 patients with IBD (8 UC) indicating efficacy.
41. Kozarek RA, Patterson DJ, Gelfand MD, et al.: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110:353-356. Series of 21 patients (7 with UC) demonstrating response in about 70%.
42. Oren R, Arber N, Odes S, et al.: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110:1416-1421. Controlled trial on 67 patients using oral methotrexate failing to show an effect in chronic active UC.
43. Kozarek RA, Patterson DJ, Ball TJ, et al.: Does oral methotrexate (MTX) therapy maintain clinical remission in inflammatory bowel disease (IBD)? Gastroenterology 1989 96:A272. Report on 21 patients indicating maintenance efficacy of methotrexate, published only as an abstract.
44. Kozarek RA, Bredfeldt JE, Rosoff LE, et al.: Does chronic methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? Gastroenterology 1991, 100:A222. Report on 68 patients with IBD indicating that no significant hepatotoxicity is found with methotrexate treatment, published only as an abstract.
45. Kozarek RA: Methotrexate and ulcerative colitis: Wrong drug? Wrong dose? Or wrong disease? Gastroenterology 1996, 110:1652-1656. Thoughtful discussion of open questions involving methotrexate in UC.
46. Brynskov J, Freund L, Thomsen OO, et al.: Treatment of refractory ulcerative colitis with cyclosporine enemas [letter]. Lancet 1989, 333:721-722. Early report on cyclosporin enemas in distal colitis.
47. Sandborn WJ, Tremaine WJ, Schroeder KW, et al.: Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993, 88:640-645. Open trial in 10 patients indicating response in 50% to cyclosporin enemas.
48. Winter TA, Dalton HR, Merreti MN, et al.: Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'. Scand J Gastroenterol 1993, 28:701-704. Open study of 12 patients indicating response in 66%.
49. Sandborn WJ, Tremaine WJ, Schroeder KW, et al.: A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994, 106:1429-1435. Controlled trial in 40 patients demonstrating no effect of cyclosporin enemas in mildly to moderately active distal UC.
50. Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1:48-63. Excellent review on cyclosporin therapy in IBD.
51. Actis GC, Ottobrelli A, Pera A, et al.: Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993, 17:10-13. Report on eight patients avoiding colectomy with intravenous cyclosporin (4 and 2 mg/kg/day).
52. Baker K, Jewell DP: Cyclosporin for the treatment of severe inflammatory bowel disease. Aliment Pharmacol Ther 1989, 3:143-149. Pilot study in 12 patients with Crohn's disease and 12 with UC indicating some efficacy of oral cyclosporin.
53. Gupta S, Keshavarzian A, Hodgson HJF: Cyclosporin in ulcerative colitis. Lancet 1984, 324:1277-1278. Early report on the use of cyclosporin in UC.
54. Bianchi Porro G, Panza E, Petrillo M: Cyclosporin A (CyA) in the treatment of acute ulcerative colitis. Z Gastroenterol 1986, 44(suppl. 1):AXXIV. Early report on four patients with UC treated with oral cyclosporin, published only as an abstract.
55. Actis GC, Ottobrelli A, Lagget N, et al.: Intravenous cyclosporin (CY-A) for refractory ulcerative colitis (UC). A phase II study to reduce dose and toxicity. Gastroenterology 1994, 106:A642. Study using a reduced dose of intravenous cyclosporin indicating efficacy in 75% of cases, published only as an abstract.
56. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845. Controlled trial showing that intravenous cyclosporin induces remission in severe refractory UC in more than 80% of patients.
57. Santos J, Baudet S, Casellas F, et al.: Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995, 20:285-289. Report on intravenous cyclosporin in 21 patients showing improvement in 76%.
58. Baert F, Hanauer S: CYA in severe steroid-resistant UC: long-term results of therapy. Gastroenterology 1994, 106:A648. Report on 18 patients treated with intravenous cyclosporin giving a response of 66%, published only as an abstract.
59. Annese V, Napolitano G, Accadia L, et al.: High doses of steroids are effective in cyclosporine A (CSA) resistant severe ulcerative colitis. Gastroenterology 1994, 106:A645. Interesting study showing that high dose steroids can be effective in cyclosporin-resistant patients, published only as an abstract.
60. Fleshner PR, Michelassi F, Rubin M, et al.: Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995, 38:1241-1245. Interesting study showing that cyclosporin treatment does not lead to increased morbidity when surgery is required.
61. Kozarek RA, Bedard C, Patterson D, et al.: Cyclosporin use in the precolectomy chronic ulcerative colitis patient: a community experience and its relationship to prospective and controlled clinical trials. Am J Gastroentrol 1995, 90:2093-2096. Community study showing little usage of cyclosporin treatment and moderate efficacy.
62. Prokupek DA, Kashyap PK, Targan SR, et al.: Cyclosporin in the treatment of refractory UC: clinical determinants of a successful outcome at 6 months. Gastroenterology 1994, 106:A756. Study on 12 patients indicating that those responding to cyclosporin are younger, have longer disease duration and less often pancolitis and probably less severe disease, published only as an abstract.
63. Sandborn WJ, Tremaine WJ, Lawson GM: Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol 1996, 91:37-43. Study showing that clinical response to cyclosporin in Crohn's disease is not related to intestinal or blood levels.
64. Van Gossum A, Schmit A, Adler M, et al.: Administration of cyclosporine in acute severe ulcerative colitis: short-term efficacy and long-term outcome. Gastroenterology 1996, 110:A1035. Study showing that long-term response to cyclosporin is less than 50%, published only as an abstract.
65. Stange EF, Modigliani R, Pena AS, et al.: European trial of cyclosporine in chronic active Crohn's disease. Gastroenterology 1995, 109:774-782. Excellent controlled trial demonstrating no therapeutic effect of cyclosporin in chronic active Crohn's disease.
66. Sternthal M, George J, Kornbluth A, et al.: Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease (IBD). Gastroenterology 1996, 110:A1019. Report on 111 patients treated with intravenous cyclosporin showing significant toxicity, published only as an abstract.
67. Korelitz BI: My thoughts on using cyclosporine in the treatment of inflammatory bowel disease. Am J Gastroenterol 1995, 90:2085-2086. Thoughtful discussion of the use of cyclosporin in IBD.
68. Bertschinger P, Himmelmann A, Risti B, et al.: Cyclosporine treatment of severe ulcerative colitis during pregnancy [letter]. Am J Gastroenterol 1995, 90:330. Interesting case report of cyclosporin treatment during pregnancy.
69. Treem WR, Cohen J, Davis PM, et al.: Cyclosporine for the treatment of fulminant ulcerative colitis in children. Dis Colon Rectum 1995, 38:474-479. Open trial in children giving a response rate of 78% to oral application.
70. Mahdi C, Israel DM, Hassal E: Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am J Gastroenterol 1996, 91:1355-1359. Open trial in 10 children using intravenous cyclosporin demonstrating 70% response.
71. Bertrán X, Fernández-Baríares F, Esteve M, et al.: Usefulness of azathioprine (AZA) to maintain cyclosporine (CyA)-induced remission in severe steroid-refractory inflammatory bowel disease (IBD). Gastroenterology 1995, 108:A782. Early report proposing azathioprine for maintenance of cyclosporin-induced remission, published only as an abstract.
72. Sewell KL: Immunotherapy and other novel therapies, including biologic response modifiers, apheresis, and dietary modifications. Curr Opin Rheumatol 1993, 5:293-298. Excellent review on immunosuppresants and other new developments in inflammatory disorders.
73. Goenka MK, Kochhar R, Tandia B, et al.: Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine. Am J Gastroenterol 1996, 91:917-921. Report of a controlled trial showing 60% response to chloroquine in active UC.
74. Mayer L, Sachar DB, Present DH, et al.: Randomized, double-blind, placebo-controlled trial of hydroxychloroquine (Plaquenil®) in the treatment of ulcerative colitis. Gastroenterology 1992, 102:A661. Controlled trial in 90 patients showing no response to hydroxychloroquine, published only as an abstract.
75. Sümer N, Palabiyikoglu M: Induction of remission by interferon-α in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995, 7:597-602. Report of 28 patients showing 82% response to α-interferon in chronic UC.
76. Boerr LAR, Sambuelli A, Gil A, et al.: Alpha-interferon was not effective treatment of patients with ulcerative colitis. Gastroenterology 1996, 110:A868. Study on 10 patients showing no response to α-interferon, published only as an abstract.
77. Baeart F, Rutgeerts P: Interferon-α: an efficacious immune-modulating therapy for ulcerative colitis? Eur J Gastroenterol Hepatol 1995, 7:593-594. Review of interferon treatment for UC questioning its use.
78. Musch E, Jüntgen C, Witzke O, et al.: Successful therapy of colitis ulcerosa by beta-interferon. Gut 1995, 38(suppl. 2):A141. Report of treatment with interferon-beta showing remission in 9 of 16 patients, published only as an abstract.
79. Van Dullemen H, Van Deventer S, Hommes D, et al.: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135. First report of successful treatment of Crohn's disease with anti-TNF.
80. 2) for treatment of patients with active Crohn's disease. Gastroenterology 1996, 110:A1026. Report of a controlled trial in refractory Crohn's disease showing remission in 35 and response in 66%, published only as an abstract.
81. Baert F, D'Haens G, Geboes K, et al.: TNF-α antibody therapy causes a fast and dramatic decrease of histologic colonic inflammation in Crohn's disease but not in ulcerative colitis. Gastroenterology 1996, 110:A859. Report indicating a lack of histological response to anti-TNF in UC, published only as an abstract.
82. Sands BE, Podolsky DK, Tremaine WJ, et al.: Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe steroid-refractory ulcerative colitis (UC). Gastroenterology 1996, 110:A1008. Report of a controlled trial of anti-TNF in refractory UC showing little effect, published only as an abstract.
83. Evans RC, Clart L, Heath P, et al.: Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571. Gastroenterology 1996, 110:A905. Report on 15 patients with UC treated with anti-TNF (human) showing some response in mild to moderately active disease, published only as an abstract.
84. Kojouharoff G, Hans W, Obermeier F, et al.: Neutralization of tumor necrosis factor but not of interleukin-1 reduces inflammation in chronic dextran sulfate sodium induced colitis in mice. Clin Exp Immunol 1997, 107:353-358. Experimental study showing no response to anti-TNF in active colitis but a response in chronic colitis.
85. Kam L, Casini-Raggi V, Cominelli F: Pentoxifylline: a novel treatment for ulcerative colitis. Gastroenterology 1995, 108:A845. First report showing clinical efficacy of pentoxifylline in active UC, published only as an abstract.
86. Van Deventer SJH, Wilson CO, Fedorak RN et al.: Safety, tolerance, pharmacokinetics and pharmacodynamics of recombinant interleukin-10 (SCH 52000) in patients with steroid refractory Crohn's disease. Gastroenterology 1996, 110:A1034. Study showing safety and some efficacy of interleukin-10 in Crohn's disease, published only as an abstract.
87. Schreiber S, Heinig T, Thiele H-C, et al.: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108:1434-1444. Three patients improving after interleukin-10 enemas are included in this paper.
88. Echtenacher B, Falk W, Männel DN, et al.: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1995, 145:3762-3766. Experimental study showing deleterious effects of anti-TNF on intestinal perforations.
89. Sawada K, Ohnishi K, Kosaka T, et al.: Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. Gastroenterology 1995, 30:124-127. Report on 44 patients with IBD (25 UC) treated with leucocytapheresis showing response in 84% and maintenance in 76% of patients with UC.
90. Kitano A, Matsumoto T, Nakamura S, et al.: New treatment of ulcerative colitis with K-76. Dis Colon Rectum 1992, 35:560-567. Report on 26 patients treated with the complement inhibitor K-76, showing response in 11 patients.
91. Levine DS, Fischer SH, Christie DL, et al.: Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol 1992, 87:91-100. Report on intravenous immunoglobulin therapy in refractory ulcerative or Crohn's colitis showing some response.
92. Emmrich J, Seyfarth M: Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 1991, 338:570-571. Report on three patients treated successfully with anti-CD4 monoclonal antibody.
93. Gaffney PR, Doyle CT, Caffney A, et al.: Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995, 90:220-223. Interesting series of 10 patients with 'difficult' UC treated successfully with heparin.
94. Brazier F, Yzet T, Dessaint C, et al.: Effect of heparin on interleukin-6 and tumor necrosis factor a serum levels in inflammatory bowel diseases. Gastroenterology 1996, 110:A872. Study demonstrating a rapid decrease of cytokines during 1 week of heparin treatment, published only as an abstract.
95. Taniguchi T, Tsukada H, Nakamura H, et al.: The effects of the anti-ICAM-1 monoclonal antibody on acute DSS colitis. Gastroenterology 1996, 110:A1025. Experimental study on the effect of anti-ICAM-1 antibodies in colitis, published only as an abstract.
96. Van Hogezand RA, Verspaget HW: Selective immunomodulation in patients with inflammatory bowel disease - future therapy or reality? Netherlands J Med 1996, 48:64-67. Thoughtful review on selective immunomodulation in IBD.